• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Laser Florence 2017: Advances in Laser Medicine >Low level laser therapy (photobiomodulation) for the management of breast cancer-related lymphedema: An update
【24h】

Low level laser therapy (photobiomodulation) for the management of breast cancer-related lymphedema: An update

机译：低水平激光疗法（光生物调节）治疗与乳腺癌相关的淋巴水肿：最新进展

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Breast cancer related lymphedema (BCRL) is prevalent among breast cancer survivors, and may be painful and disfiguring with associated psychological impact. Previous research shows increasing use of low level laser therapy (LLLT), now commonly referred to as photobiomodulation (PBM) therapy, in countries including the United States and Australia, for managing BCRL. However, conclusions were limited by the paucity, heterogeneity, and poor study quality. LLLT (PBM) has been barely used in clinical practice in New Zealand, and no clinical studies on LLLT (PBM) for BCRL have been conducted in this country. In order to promote this potentially useful treatment modality for BCRL patients, the Laser Lymphedema Trial Team at the University of Otago conducted a program to assess the effectiveness of LLLT (PBM) in management of BCRL. The program comprises three phases including a systematic review (completed), a feasibility study (completed), and a full-scale randomized controlled trial (proposed). This current paper provides an update on the program. Based upon the systematic review, LLLT (PBM) is considered an effective treatment approach for women with BCRL; the review also indicated the need for further research including exploration of the relevance of dosage and other LLLT (PBM) parameters. The feasibility study demonstrated that it is feasible to conduct a fully powered RCT to definitively test the effectiveness of the additional use of LLLT (PBM) in the management of BCRL, and 114 participants will be needed at baseline in the main study. Currently, the full-scale RCT is under preparation.
机译：乳腺癌相关淋巴水肿（BCRL）在乳腺癌幸存者中普遍存在，可能会带来痛苦和毁容，并伴有相关的心理影响。先前的研究表明，在包括美国和澳大利亚在内的国家中，越来越多的人使用低水平激光疗法（LLLT）（现在通常称为光生物调节（PBM）治疗）来管理BCRL。但是，结论受到缺乏，异质性和不良研究质量的限制。 LLLT（PBM）几乎没有在新西兰的临床实践中使用，并且该国尚未进行针对BCRL的LLLT（PBM）的临床研究。为了向BCRL患者推广这种潜在有用的治疗方式，奥塔哥大学的激光淋巴水肿试验小组实施了一项计划，以评估LLLT（PBM）在治疗BCRL中的有效性。该计划包括三个阶段，包括系统评价（已完成），可行性研究（已完成）和全面随机对照试验（拟议）。本白皮书提供了该程序的更新。根据系统评价，LLLT（PBM）被认为是治疗BCRL女性的有效方法；审查还表明需要进一步研究，包括探索剂量与其他LLLT（PBM）参数的相关性。可行性研究表明，进行功能强大的RCT来明确测试在BCRL管理中额外使用LLLT（PBM）的有效性是可行的，主要研究中的基线需要114名参与者。目前，正在准备全面的RCT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号